GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (FRA:JSS) » Definitions » Research & Development

Nxera Pharma Co (FRA:JSS) Research & Development : €71.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Nxera Pharma Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Nxera Pharma Co's Research & Development for the three months ended in Mar. 2024 was €19.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €71.4 Mil.

Nxera Pharma Co Research & Development Historical Data

The historical data trend for Nxera Pharma Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Research & Development Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.41 30.04 46.11 52.16 64.17

Nxera Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.68 13.59 18.85 19.50 19.42

Nxera Pharma Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €71.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co  (FRA:JSS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nxera Pharma Co Research & Development Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co (FRA:JSS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (FRA:JSS) » Definitions » Research & Development
Comparable Companies
TSE:2160 TSE:4587 TSE:4974 TSE:4599 TSE:4880 TSE:4592 TSE:7096 TSE:7774 TSE:4978 TSE:4893 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
SOLTF:USA 4565:Japan JSS:Germany
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Website
http://www.sosei.com
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (FRA:JSS) Headlines

No Headlines